SG Americas Securities
MTNB icon

SG Americas Securities’s Matinas BioPharma MTNB Stock Holding History

SG Americas Securities’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,347
Closed -$100K – 3796
2020
Q1 		$100K Sell
3,347
-1,668
-33% -$101K ﹤0.01% 3011
2019
Q4 		$569K Buy
+5,015
New +$291K 0.01% 1662
2018
Q1 		– Sell
-863
Closed -$50K – 3445
2017
Q4 		$50K Buy
863
+38
+5% +$2.44K ﹤0.01% 2974
2017
Q3 		$54K Buy
+825
New +$55.1K ﹤0.01% 3310

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

SG Americas Securities's MTNB Position: Q2 2020 in Review

SG Americas Securities sold out of Matinas BioPharma (MTNB) in Q2 2020, closing a stake of 3,347 shares — an estimated $100K sold.

SG Americas Securities first reported a position in MTNB in Q3 2017 and held it in 4 quarters. The position peaked at $569K in Q4 2019. 65 funds tracked by Wall St. Rank hold MTNB as of Q2 2020.

  • SG Americas Securities reported no remaining Matinas BioPharma position as of Q2 2020 after selling out during the quarter.
  • SG Americas Securities sold 3,347 Matinas BioPharma shares in Q2 2020, an estimated $100K.
  • SG Americas Securities first reported a position in Matinas BioPharma in Q3 2017 and held it in 4 quarters.
  • SG Americas Securities's Matinas BioPharma position peaked at $569K in Q4 2019.
  • 65 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2020.

Based on SG Americas Securities's 13F filing for Q2 2020, filed 20 Jul 2020.